Русский
Therapeutic efficacy and safety of monotherapy Alfuprost® MR 10 mg/day in clinical practice
DOI: https://dx.doi.org/10.18565/urology.2022.2.11-17
A.I. Novikov, E.S. Shpilenya
1) Department of Oncourology of State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care, Saint Petersburg, Russia; 2) Department of urology (Head - prof. B.K. Komyakov) of North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
Introduction. Alpha-blockers are the first-line therapy for men with BPH/LUTS. They have similar efficiency, but different uroselectivity. Therefore, when choosing a-blockers, their safety and adverse events should be taken into account.
Aim. To evaluate the efficiency and safety of using Alfuprost® MR 10 mg/day for 12 months in clinical practice.
Materials and methods. A total of 55 men aged 55-80 years with BPH/ LUTS were included in the study, which was carried out on the basis of 6 outpatient clinics in St. Petersburg from June 2020 to September 2021. Along with standard methods, the examination included an assessment of male sexual function, hemodynamic parameters, and satisfaction with the treatment of patients and physicians using the Likert scale. The follow-up scheme included 7 visits (every 60±5 days) and lasted 12 months.
Results. After 2 months of therapy with Alfuprost® MR, a significant decrease in the number of patients complaining of pain was observed. The proportion of patients with urgency and difficulty with urinating decreased by 50% and 30%, respectively. By the end of the treatment, the total IPSS score decreased by 1.9 times and averaged 9.98 points, the quality of life improved by 2.5 points, the average maximum urine flow rate significantly increased by 1.4 times, reaching 17.4 ml/sec, and the post-void residual volume decreased to 12.5 ml (3.8 times). By the last visit, there was a decrease in prostate volume by 4.3%. Moreover, the proportion of patients with an initial level of total PSA 2.5-4 ng/ml decreased by 25.4%. The level of PSA after treatment less than 2.5 ng/ml was seen in 70.9% of cases. All patients were satisfied with the treatment after 2 months, as well as investigators at visit 5. There was a significant improvement in all components of the sexual function, especially erectile function. In addition, there were no significant changes in ejaculation.
Conclusion. Long-term therapy with Alfuprost® MR 10 mg/day has high therapeutic efficacy and safety in elderly patients with LUTS/BPH, regardless of comorbidities.
Aim. To evaluate the efficiency and safety of using Alfuprost® MR 10 mg/day for 12 months in clinical practice.
Materials and methods. A total of 55 men aged 55-80 years with BPH/ LUTS were included in the study, which was carried out on the basis of 6 outpatient clinics in St. Petersburg from June 2020 to September 2021. Along with standard methods, the examination included an assessment of male sexual function, hemodynamic parameters, and satisfaction with the treatment of patients and physicians using the Likert scale. The follow-up scheme included 7 visits (every 60±5 days) and lasted 12 months.
Results. After 2 months of therapy with Alfuprost® MR, a significant decrease in the number of patients complaining of pain was observed. The proportion of patients with urgency and difficulty with urinating decreased by 50% and 30%, respectively. By the end of the treatment, the total IPSS score decreased by 1.9 times and averaged 9.98 points, the quality of life improved by 2.5 points, the average maximum urine flow rate significantly increased by 1.4 times, reaching 17.4 ml/sec, and the post-void residual volume decreased to 12.5 ml (3.8 times). By the last visit, there was a decrease in prostate volume by 4.3%. Moreover, the proportion of patients with an initial level of total PSA 2.5-4 ng/ml decreased by 25.4%. The level of PSA after treatment less than 2.5 ng/ml was seen in 70.9% of cases. All patients were satisfied with the treatment after 2 months, as well as investigators at visit 5. There was a significant improvement in all components of the sexual function, especially erectile function. In addition, there were no significant changes in ejaculation.
Conclusion. Long-term therapy with Alfuprost® MR 10 mg/day has high therapeutic efficacy and safety in elderly patients with LUTS/BPH, regardless of comorbidities.
Keywords: alpha-1 blockers, Benign Prostatic Hyperplasia (BPH), lower urinary tract symptoms (LUTS), alfuzosin
About the Autors
Corresponding author: Novikov A.I. - Ph.D., MD, professor at the Department of Urology of FGBOU VO North-Western State Medical University named after I.I. Mechnikov, Head of the Department of Oncourology of State Budgetary Healthcare Institution «Saint-Petersburg clinical scientific and practical center for specialised types of medical care, Saint Petersburg, Russia; novikov_urol@mail.ru
Similar Articles
